333 related articles for article (PubMed ID: 26697986)
1. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986
[TBL] [Abstract][Full Text] [Related]
2. Ultrastructural features and expression of cytoskeleton proteins of podocyte from patients with minimal change disease and focal segmental glomerulosclerosis.
Shi SF; Wang SX; Zhang YK; Zhao MH; Zou WZ
Ren Fail; 2008; 30(5):477-83. PubMed ID: 18569926
[TBL] [Abstract][Full Text] [Related]
3. Cell-cycle regulatory proteins in the podocyte in collapsing glomerulopathy in children.
Srivastava T; Garola RE; Singh HK
Kidney Int; 2006 Aug; 70(3):529-35. PubMed ID: 16775597
[TBL] [Abstract][Full Text] [Related]
4. CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood.
Eroglu FK; Orhan D; İnözü M; Duzova A; Gulhan B; Ozaltin F; Topaloglu R
Pediatr Int; 2019 Dec; 61(12):1250-1256. PubMed ID: 31513327
[TBL] [Abstract][Full Text] [Related]
5. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
6. Reduced INF2 expression in nephrotic syndrome is possibly related to clinical severity of steroid resistance in children.
Tamura H; Nakazato H; Kuraoka S; Yoneda K; Takahashi W; Endo F
Nephrology (Carlton); 2016 Jun; 21(6):467-75. PubMed ID: 26383224
[TBL] [Abstract][Full Text] [Related]
7. Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients.
Navarro-Muñoz M; Ibernon M; Pérez V; Ara J; Espinal A; López D; Bonet J; Romero R
Nephrol Dial Transplant; 2011 Dec; 26(12):3914-23. PubMed ID: 21414970
[TBL] [Abstract][Full Text] [Related]
8. [The clinic significance of urinary podocytes in patients with focal segmental glomerulosclerosis].
Li YH; Huang HC; Liu G; Zhang YK
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):135-8. PubMed ID: 15100729
[TBL] [Abstract][Full Text] [Related]
9. The role of B7-1 in proteinuria of glomerular origin.
Novelli R; Benigni A; Remuzzi G
Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of fibroblast-specific protein-1 expression on podocytes in patients with focal segmental glomerulosclerosis.
Samejima K; Nakatani K; Suzuki D; Asai O; Sakan H; Yoshimoto S; Yamaguchi Y; Matsui M; Akai Y; Toyoda M; Iwano M; Saito Y
Nephron Clin Pract; 2012; 120(1):c1-7. PubMed ID: 22126861
[TBL] [Abstract][Full Text] [Related]
11. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.
Eriguchi M; Yotsueda R; Torisu K; Kawai Y; Hasegawa S; Tanaka S; Noguchi H; Masutani K; Kitazono T; Tsuruya K
Am J Physiol Renal Physiol; 2016 Feb; 310(4):F322-33. PubMed ID: 26632605
[TBL] [Abstract][Full Text] [Related]
12. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
[TBL] [Abstract][Full Text] [Related]
13. Glomerular malondialdehyde levels in patients with focal and segmental glomerulosclerosis and minimal change disease.
Nezhad ST; Momeni B; Basiratnia M
Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):886-91. PubMed ID: 20814126
[TBL] [Abstract][Full Text] [Related]
14. Urinary CD80 as a Replacement for Renal Biopsy for Diagnosis of Pediatric Minimal Change Disease.
Ahmed HM; Ezzat DA; Doudar NA; Adel M
Iran J Kidney Dis; 2018 Mar; 12(2):107-111. PubMed ID: 29507273
[TBL] [Abstract][Full Text] [Related]
15. Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies.
Pereira LHM; da Silva CA; Monteiro MLGDR; Araújo LS; Rocha LP; Reis MBDR; Ramalho FS; Corrêa RRM; Silva MV; Reis MA; Machado JR
PLoS One; 2019; 14(6):e0217569. PubMed ID: 31188898
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.
Hansrivijit P; Puthenpura MM; Ghahramani N
Clin Nephrol; 2020 Sep; 94(3):117-126. PubMed ID: 32589135
[TBL] [Abstract][Full Text] [Related]
17. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
Cara-Fuentes G; Venkatareddy M; Verma R; Segarra A; Cleuren AC; Martínez-Ramos A; Johnson RJ; Garg P
Pediatr Nephrol; 2020 Oct; 35(10):1887-1896. PubMed ID: 32399663
[TBL] [Abstract][Full Text] [Related]
18. Minimal change disease and idiopathic FSGS: manifestations of the same disease.
Maas RJ; Deegens JK; Smeets B; Moeller MJ; Wetzels JF
Nat Rev Nephrol; 2016 Dec; 12(12):768-776. PubMed ID: 27748392
[TBL] [Abstract][Full Text] [Related]
19. Ezrin--a useful factor in the prognosis of nephrotic syndrome in children: an immunohistochemical approach.
Ostalska-Nowicka D; Zachwieja J; Nowicki M; Kaczmarek E; Siwinska A; Witt M
J Clin Pathol; 2006 Sep; 59(9):916-20. PubMed ID: 16522749
[TBL] [Abstract][Full Text] [Related]
20. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.
Pérez V; López D; Boixadera E; Ibernón M; Espinal A; Bonet J; Romero R
BMC Nephrol; 2017 Feb; 18(1):49. PubMed ID: 28158993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
